Crossmark

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs

Crossref DOI link: https://doi.org/10.1007/s40256-018-0312-1

Published Online: 2018-12-19

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Takata, Kohei

Nicholls, Stephen J.
License Information

Text and Data Mining valid from 2018-12-19
More Information

Article History

First Online: 19 December 2018

Compliance with Ethical Standards

:

: None.

: Stephen J. Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough and Takeda, consulting fees from AstraZeneca, Abbott, Atheronova, Esperion, Amgen, Novartis, Omthera, CSL Behring, Boehringer Ingelheim, Pfizer, Merck Schering-Plough, Takeda, Roche, Novo Nordisk, LipoScience and Anthera, and research support from the National Health and Medical Research Council of Australia, Anthera, AstraZeneca, Cerenis, Eli Lilly, InfraReDx, Roche, Resverlogix, Novartis, Amgen, and LipoScience. Kohei Takata has reported that he has no relationships to disclose.